ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms
A multicenter Phase II clinical trial has demonstrated significant tumour shrinkage and disease control in patients…
Browsing: ESMO
ESMO 2025: Novel treatment combination improves progression-free survival in metastatic, oestrogen-receptor-positive HER-2-negative breast cancer
Patients with oestrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with…
ESMO 2025: Chemo combination boosts overall survival in patients with EGFR-mutant NSCLC
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful…
ESMO 2025: Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
A drug that harnesses the immune system to attack cancer cells has proved successful in…
ESMO 2024: Breastfeeding after breast cancer is safe
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after…
ESMO 2024: Combination therapy reduced agitated delirium in patients with advanced cancers
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common…
ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer
Studies reported at ESMO 2024 have revealed new groups of women with early-stage (1) and…
ESMO 2024: Coaching programme for increased exercise in breast cancer patients
A study on exercise for cancer patients, presented at ESMO 2024, draws on data from…
ESMO 2024: High dose vitamin D3 does not provide benefit for metastatic colorectal cancer
Data from SOLARIS (Alliance A021703), a multicenter double-blind phase III randomised clinical trial of vitamin…
ESMO 2024: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking…